We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
+$244M
Cap. Flow
+$74.7M
Cap. Flow %
4.68%
Top 10 Hldgs %
27.52%
Holding
150
New
14
Increased
55
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$36M
2
AMRN
Amarin Corp
AMRN
+$13.9M
3
TSRO
TESARO, Inc.
TSRO
+$13.7M
4
DHR icon
Danaher
DHR
+$12.8M
5
PTHN
Patheon N.V.
PTHN
+$11M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
2
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.8M
4
MD icon
Pediatrix Medical
MD
+$9.92M
5
XNPT
XENOPORT, INC.
XNPT
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
2 Financials 3.67%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
76
Ascendis Pharma A/S
ASND
$16.8B
$6.03M 0.38%
300,000
– –
ALDR
77
DELISTED
Alder Biopharmaceuticals
ALDR
$5.96M 0.37%
182,000
+1,500
+0.8% +$45.7K
JUNO
78
DELISTED
Juno Therapeutics, Inc.
JUNO
$5.91M 0.37%
197,001
– –
SRGA
79
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$5.82M 0.37%
62,000
– –
ATHN
80
DELISTED
Athenahealth, Inc.
ATHN
$5.77M 0.36%
45,750
– –
AVXS
81
DELISTED
AveXis, Inc. Common Stock
AVXS
$5.77M 0.36%
140,000
-2,758
-2% -$105K
GI
82
DELISTED
EndoChoice Holdings, Inc.
GI
$5.77M 0.36%
722,500
+12,500
+2% +$58.5K
XENT
83
DELISTED
Intersect ENT, Inc
XENT
$5.46M 0.34%
345,000
+5,000
+1% +$75.3K
CGEN icon
84
Compugen
CGEN
$228M
$5.2M 0.33%
825,000
+5,000
+0.6% +$33.9K
KDNY
85
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.16M 0.32%
83,000
– –
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$5.14M 0.32%
695,000
+15,000
+2% +$101K
KYNB
87
Kyntra Bio
KYNB
$29.4M
$4.83M 0.3%
9,340
+340
+4% +$160K
ADAP
88
DELISTED
Adaptimmune Therapeutics
ADAP
$4.76M 0.3%
675,000
-90,001
-12% -$687K
PBYI icon
89
Puma Biotechnology
PBYI
$454M
$4.66M 0.29%
69,500
+36,500
+111% +$1.85M
TNDM icon
90
Tandem Diabetes Care
TNDM
$1.56B
$4.56M 0.29%
59,500
– –
CLVS
91
DELISTED
Clovis Oncology, Inc.
CLVS
$4.51M 0.28%
125,000
– –
CO
92
DELISTED
Global Cord Blood Corporation
CO
$4.5M 0.28%
880,000
– –
KITE
93
DELISTED
Kite Pharma, Inc.
KITE
$4.41M 0.28%
79,000
-1,000
-1% -$55.7K
AIMT
94
DELISTED
Aimmune Therapeutics
AIMT
$4.39M 0.28%
293,000
– –
OPCH icon
95
Option Care Health
OPCH
$3.56B
$4.31M 0.27%
+372,623
New +$4.02M
AGN.PRA
96
DELISTED
Allergan plc
AGN.PRA
$4.11M 0.26%
5,000
– –
MEDP icon
97
Medpace
MEDP
$16.5B
$4.03M 0.25%
+135,000
New +$3.94M
ALPN
98
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.98M 0.25%
122,250
– –
OTIC
99
DELISTED
Otonomy, Inc.
OTIC
$3.82M 0.24%
210,000
-30,000
-13% -$490K
CORV
100
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$3.75M 0.24%
1,200,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rock Springs Capital Management held 150 positions worth $1.6B, up 18% from $1.35B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $74.7M of net new capital in Q3 2016, opening 14 new positions and adding to 55 existing holdings. Its largest new stake was Merck: 615,700 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Pediatrix Medical, an estimated $9.92M trimmed.

  • Rock Springs Capital Management's largest Q3 2016 buy was Merck: 615,700 shares worth $36.7M.
  • Rock Springs Capital Management added most to TESARO, Inc. in Q3 2016, an estimated $13.7M increase.
  • Rock Springs Capital Management's biggest Q3 2016 reduction was Pediatrix Medical, cutting an estimated $9.92M.
  • Rock Springs Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.6B portfolio in Q3 2016.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q3 2016.
  • Rock Springs Capital Management's portfolio value rose 18% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.